Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4897724 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3SIGMAR1CA2CA12 | |
| SCHEMBL30733932 | 0.80 | CHRM5 (0.53) | CHRM5CHRM3SIGMAR1CA2CA12 | |
| SCHEMBL62989 | 0.78 | CHRM5 (0.52) | CHRM5CHRM3SIGMAR1CA2CA12 | |
| SCHEMBL337070 | 0.78 | HSD17B10 (0.52) | CHRM5CHRM3SIGMAR1CA2CA12 | |
| SCHEMBL62990 | 0.78 | HSD17B10 (0.52) | CHRM5CHRM3SIGMAR1CA2CA12 | |
| SCHEMBL1675859 | 0.77 | — | — | |
| SCHEMBL24247411 | 0.76 | CHRM5 (0.55) | CHRM5CHRM3SIGMAR1CA2CA12 | |
| SCHEMBL472213 | 0.76 | CHRM5 (0.50) | CHRM5CHRM3SIGMAR1CA2CA12 | |
| SCHEMBL8038 | 0.76 | CHRM5 (0.55) | CHRM5CHRM3SIGMAR1CA2CA12 | |
| SCHEMBL24753933 | 0.76 | CHRM5 (0.50) | CHRM5CHRM3SIGMAR1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786304-B2 | Process for the preparation of eszopiclone | CENTAUR PHARMACEUTICAL PVT. LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-20080146800-A1 | Process for the preparation of eszopiclone | CENTAUR PHARMACEUTICAL PVT. LTD. (IN) | 2008-06-19 | — | — | US | disclosed |
| EP-1904499-A1 | PROCESS FOR THE PREPARATION OF ZOPICLONE | Teva Pharmaceutical Industries Ltd (IL) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008002629-A1 | PROCESS FOR THE PREPARATION OF ZOPICLONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-01-03 | — | — | WO | disclosed |
| US-4891378-A | CEREBRAL INSUFFICIENCY | BOEHRINGER INGELHEIM ZENTRALE GMBH (DE) | 1990-01-02 | — | — | US | disclosed |
| US-4857528-A | Substituted pyrrolidinones, pharmaceutical compositions and use | BOEHRINGER INGELHEIM KG (DE) | 1989-08-15 | — | — | US | disclosed |
| US-4762832-A | TREATING CEREBRAL INSUFFICIENCY | BOEHRINGER INGELHEIM KG (DE) | 1988-08-09 | — | — | US | disclosed |
| EP-0163260-B1 | NOVEL SUBSTITUTED PYRROLIDINONES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICS | BOEHRINGER INGELHEIM KG (DE) | 1988-08-03 | — | — | EP | disclosed |
| US-4670456-A | 4-Aminocarbonylaminomethyl-1-benzylpyrrolidin-2-ones as nootropic agents and as agents for treating cerebral insufficiency | BOEHRINGER INGELHEIM KG (DE) | 1987-06-02 | — | — | US | disclosed |
| EP-0163260-A1 | Novel substituted pyrrolidinones, process for their manufacture and pharmaceutics | BOEHRINGER INGELHEIM KG (DE) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146800-A1 | Process for the preparation of eszopiclone | CYP3A5, CYP3A7, CYP51A1 | CHRM5 304/4885CHRM3 622/4885SIGMAR1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.